Although we performed a series of in-vivo and in-vitro functional assays and reversion experiments to confirm that the expression levels of JWA and CTBP1 were necessary for JAC4 to exert its anti-cancer function, we still cannot exclude other downstream molecules that may be involved in the onset of the anti-tumor mechanism of JAC4, which requires further investigation. The gene discussed is ARL6IP5; the disease is cancer.